GTx Inc. has partnered with Merck and Co. Inc. in a deal worth at least $500 million to develop and commercialize selective androgen receptor modulators (SARMs), a new class of drugs that target musculoskeletal conditions, such as age-related muscle loss. (BioWorld Today) Read More
